A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-03

Study Completion Date

2019-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Trial Objective: To investigate the safety, tolerability, PK, and PD following single ascending doses of HBM9161 in healthy Chinese subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

NCT06716151

Healthy

RECRUITING PHASE1

Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

NCT04213196

Healthy Volunteers

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

NCT04652297

Healthy

UNKNOWN PHASE1

A Trial of CRB4101 in Healthy Subjects

NCT05641181

Healthy Adult Subjects

UNKNOWN PHASE1

A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

NCT06504043

Hypercholesterolemia Healthy Volunteers LDL-Cholesterol

ENROLLING_BY_INVITATION PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HBM9161(HL161BKN) is a human monoclonal antibody. HBM9161 targets the neonatal Fc receptor (FcRn) . The neonatal FcRn is a potential therapeutic target for many autoimmune diseases. This Phase I study will evaluate the safety, tolerability, PK, and PD of subcutaneous (SC) doses of HBM9161(HL161BKN) (abbreviated as HBM9161) in healthy Chinese subjects. Up to 24 healthy Chinese subjects will be randomized into the study. For each dose group, 8 subjects will be randomized (6 subjects to HBM9161 group and 2 subjects to placebo group).

This study will also provide guidance on doses to be used in future studies involving patients with autoimmune diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Chinese Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Subcutaneous injection; Single dose on Day 1

Intervention Type DRUG

Placebo

Subcutaneous injection; Single dose on Day 1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Han Chinese male or female subjects, and his/her biological parents and grandparents are of Han Chinese ethnicity.
2. Body weight ≥ 50kg with BMI ≥19.0 and \<=24.0 kg/m2 at screening and baseline visit.
3. Generally, in good health with no clinically significant abnormalities as determined by medical history, physical examination, 12-lead ECG and clinical laboratory tests.

Exclusion Criteria

1. Subject has a total IgG level of \< 700mg/dL at screening.
2. Subject has an active infection or has had a serious infection within 6 weeks prior to Day -1 or infection requiring oral anti-infective agents within 2 weeks prior to Day-1, or subject had a febrile illness or symptomatic, viral, bacterial, or fungal infection within 1 week prior to admission (Day -1).
3. History of relevant allergy/hypersensitivity (including allergy to study drug or its excipients).
4. Any laboratory values outside the reference range that are of clinical significance according to investigator's clinical judgement.
5. Subject has estimated creatinine clearance ≤ 80 mL/min calculated by Cockcroft Gault formula at screening.
6. Subject has any ECG abnormality defined in the protocol (a single repeat will be allowed for eligibility determination) at screening or Day -1:
7. Positive HIV test result at screening.
8. Positive testing for HBs Antigen and/or a positive Hepatitis C antibody test result at screening.
9. Subject has a positive T-cell interferon-γ release assay (TIGRA) result
10. Subjects who had immunization within 4 weeks before screening; or subjects who plan to have immunization during the study and within 12 weeks after dosing of the study drug.
11. For female subjects, positive pregnancy test at screening or Day -1, or planning to become pregnant from screening until 90 days after the dosing of the study drug.
12. Lactating female subjects.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes